{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:19:33Z","timestamp":1783592373840,"version":"3.55.0"},"reference-count":41,"publisher":"Bioscientifica","issue":"10","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The kinase inhibitors lenvatinib and sorafenib represent the first-line options for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Comparative studies in the same study population or between similar cohorts are scarce. Our objective was to compare lenvatinib and sorafenib in na\u00efve RR-DTC in a homogeneous real-life context. We performed a retrospective study involving two institutions from the Italian region Campania. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were objective response rate (ORR), disease-control rate, adverse events graded \u22653, toxicity-related treatment withdrawal, and dose reductions\/interruptions. Forty-eight RR-DTC patients were included (median follow-up 45.5 months): 24 received lenvatinib from 2015 to 2021 and 24 sorafenib from 2012 to 2016. The sorafenib group showed a higher disease-related symptoms rate (P = 0.022), tumor burden (P = 0.002), and cumulative radioiodine dose compared to lenvatinib. At univariate analysis, median PFS and OS were significantly longer for lenvatinib (30 and 53 months, respectively) compared to sorafenib (10 and 38 months, respectively) (P &amp;lt; 0.001 and = 0.037, respectively). At multivariate analysis, the significance was retained for PFS and lost for OS. ORR was higher for lenvatinib compared to sorafenib (P &amp;lt; 0.001). Dose reductions and interruptions were more frequent for lenvatinib compared to sorafenib (P = 0.003 and 0.01, respectively). In our real-life context, RR-DTC treated with first-line sorafenib had more advanced disease compared to lenvatinib. Lenvatinib exerted stronger antitumor activity (improved PFS and ORR) compared to sorafenib but did not improve OS. Sorafenib was more manageable.<\/jats:p>","DOI":"10.1530\/erc-24-0215","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:25:48Z","timestamp":1759760748000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-3887","authenticated-orcid":true,"given":"Vincenzo","family":"Marotta","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno 1 , ,","place":["Baronissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tortora","sequence":"additional","affiliation":[{"name":"2UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d\u2019Aragona, Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariafelicia","family":"Valeriani","sequence":"additional","affiliation":[{"name":"UOC Chirurgia Generale, AOU San Giovanni di Dio e Ruggi d\u2019Aragona 3 , ,","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Caleo","sequence":"additional","affiliation":[{"name":"UOC Anatomia Patologica, AOU San Giovanni di Dio e Ruggi d\u2019Aragona 4 , ,","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gaeta","sequence":"additional","affiliation":[{"name":"Laboratorio di Diagnostica Molecolare, UOC Anatomia Patologica, AOU San Giovanni di Dio e Ruggi d\u2019Aragona 5 , ,","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Infante","sequence":"additional","affiliation":[{"name":"Laboratorio di Diagnostica Molecolare, UOC Anatomia Patologica, AOU San Giovanni di Dio e Ruggi d\u2019Aragona 5 , ,","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Stanzione","sequence":"additional","affiliation":[{"name":"UOC di Chirurgia Generale, d\u2019Urgenza e di Endocrinochirurgia, Pineta Grande Hospital 6 , , ,","place":["Castel Volturno, Caserta, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Scafuri","sequence":"additional","affiliation":[{"name":"Oncology Unit, \u201cAndrea Tortora\u201d Hospital, ASL Salerno 7 , ,","place":["Pagani, Italy"]},{"name":"Associazione O.R.A. ETS-Oncology Research Assistance 8 , ,","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gambardella","sequence":"additional","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d 9 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Gennaro","sequence":"additional","affiliation":[{"name":"Struttura Complessa Medicina Nucleare e Terapia Radiometabolica-UOS Terapia Metabolica Sperimentale, Istituto Nazionale Tumori \u2013 IRCCS \u2013 Fondazione G.Pascale 10 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perri","sequence":"additional","affiliation":[{"name":"Medical and Experimental Head and Neck Oncology Unit, Istituto Nazionale Tumori \u2013 IRCCS \u2013 Fondazione G.Pascale 11 , ,","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant\u2019Andrea Hospital, ENETS Center of excellence, Sapienza University of Rome 12 , ,","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-5971","authenticated-orcid":true,"given":"Mario","family":"Vitale","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno 1 , ,","place":["Baronissi, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Pezzullo","sequence":"additional","affiliation":[{"name":"UOC di Chirurgia Generale, d\u2019Urgenza e di Endocrinochirurgia, Pineta Grande Hospital 6 , , ,","place":["Castel Volturno, Caserta, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026070905401642400_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"2026070905401642400_bib2","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1","article-title":"A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985\u20131995 [see commetns]","volume":"83","author":"Hundahl","year":"1998","journal-title":"Cancer"},{"key":"2026070905401642400_bib3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905401642400_bib4","first-page":"598","article-title":"Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma","volume":"37","author":"Schlumberger","year":"1996","journal-title":"J Nucl Med"},{"key":"2026070905401642400_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cen.12511","article-title":"The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma","volume":"82","author":"Su","year":"2015","journal-title":"Clin Endocrinol"},{"key":"2026070905401642400_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103353","article-title":"Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm","volume":"162","author":"Marotta","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026070905401642400_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905401642400_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eprac.2023.08.005","article-title":"Real-world use of systemic therapies for the treatment of advanced thyroid cancers","volume":"29","author":"Chen","year":"2023","journal-title":"Endocr Pract"},{"key":"2026070905401642400_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24020","article-title":"Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation","volume":"24","author":"Fleeman","year":"2020","journal-title":"Health Technol Assess"},{"key":"2026070905401642400_bib10","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070905401642400_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(16)31549-0","article-title":"Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis","volume":"51","author":"Guo","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026070905401642400_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(09)70160-3","article-title":"Population-based differences in treatment outcome following anticancer drug therapies","volume":"11","author":"Ma","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026070905401642400_bib13","article-title":"Recognizing the limits of the 21 different Italian healthcare regional systems: an opportunity for change?","volume":"51","author":"Piscitelli","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026070905401642400_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-0039.1980.tb00308.x","article-title":"The HLA system in the Campania region: a genetic study","volume":"16","author":"Zappacosta","year":"1980","journal-title":"Tissue Antigens"},{"key":"2026070905401642400_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.30958\/ajms.2-3-1","article-title":"Immigration in the mediterranean cities: Comparison between Italy and Turkey","volume":"2","author":"Francese","year":"2016","journal-title":"Athens J Mediterr Stud"},{"key":"2026070905401642400_bib16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.ejcn.1601719","article-title":"Dietary and nutritional patterns in an elderly rural population in Northern and Southern Italy: (I). A cluster analysis of food consumption","volume":"57","author":"Correa Leite","year":"2003","journal-title":"Eur J Clin Nutr"},{"key":"2026070905401642400_bib17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/healthcare9091182","article-title":"Inter-regional hospital patients\u2019 mobility in Italy","volume":"9","author":"Nante","year":"2021","journal-title":"Healthcare"},{"key":"2026070905401642400_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/2359-3997000000245","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation","volume":"61","author":"Schmidt","year":"2017","journal-title":"Arch Endocrinol Metab"},{"key":"2026070905401642400_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070905401642400_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2026070905401642400_bib21","doi-asserted-by":"crossref","first-page":"e3911","DOI":"10.1210\/clinem\/dgab436","article-title":"Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer","volume":"106","author":"Simoes-Pereira","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905401642400_bib22","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/clinem\/dgae181","article-title":"Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life","volume":"109","author":"Marotta","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905401642400_bib23","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-20-3868","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-friends of cancer research performance status work group","volume":"27","author":"Magnuson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070905401642400_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/thy.2022.0054","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","journal-title":"Thyroid"},{"key":"2026070905401642400_bib25","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/healthcare10102049","article-title":"Spatial and socioeconomic inequalities in accessibility to healthcare services in South Korea","volume":"10","author":"Lee","year":"2022","journal-title":"Healthcare"},{"key":"2026070905401642400_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj.EJ17-0365","article-title":"Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients","volume":"65","author":"Sugino","year":"2018","journal-title":"Endocr J"},{"key":"2026070905401642400_bib27","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/hed.25784","article-title":"Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"41","author":"Suzuki","year":"2019","journal-title":"Head Neck"},{"key":"2026070905401642400_bib28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12057","article-title":"Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET","volume":"78","author":"Marotta","year":"2012","journal-title":"Clin Endocrinol"},{"key":"2026070905401642400_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/thy.2017.0356","article-title":"Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study","volume":"28","author":"Kim","year":"2018","journal-title":"Thyroid"},{"key":"2026070905401642400_bib30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1089\/thy.2021.0091","article-title":"Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"2026070905401642400_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12020-024-03867-4","article-title":"Ten years\u2019 real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer","volume":"85","author":"Jerkovich","year":"2024","journal-title":"Endocrine"},{"key":"2026070905401642400_bib32","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1089\/thy.2019.0246","article-title":"Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study","volume":"29","author":"Oh","year":"2019","journal-title":"Thyroid"},{"key":"2026070905401642400_bib33","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1634\/theoncologist.2019-0633","article-title":"Clinicopathological features predict outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with sorafenib: a real-world study","volume":"25","author":"Cheng","year":"2020","journal-title":"Oncologist"},{"key":"2026070905401642400_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100398","article-title":"Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations","volume":"7","author":"Solomon","year":"2022","journal-title":"ESMO Open"},{"key":"2026070905401642400_bib35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1210\/clinem\/dgab731","article-title":"A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer","volume":"107","author":"Brose","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905401642400_bib36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants","volume":"387","author":"Collaboration NCDRF","year":"2016","journal-title":"Lancet"},{"key":"2026070905401642400_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12020-016-1200-6","article-title":"Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib","volume":"57","author":"Marotta","year":"2017","journal-title":"Endocrine"},{"key":"2026070905401642400_bib38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12020-014-0481-x","article-title":"Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center","volume":"49","author":"Gallo","year":"2015","journal-title":"Endocrine"},{"key":"2026070905401642400_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026070905401642400_bib40","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1089\/thy.2020.0779","article-title":"Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib","volume":"31","author":"Taylor","year":"2021","journal-title":"Thyroid"},{"key":"2026070905401642400_bib41","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/14737140.2016.1247697","article-title":"Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib","volume":"16","author":"Kawalec","year":"2016","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/10\/ERC-24-0215.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/10\/ERC-24-0215.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0215\/144572\/erc-24-0215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0215\/144572\/erc-24-0215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:40:26Z","timestamp":1783590026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/10\/e240215\/25855\/First-line-lenvatinib-and-sorafenib-in-RR-DTC-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0215","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"e240215"}}